LOS ANGELES--(BUSINESS WIRE)--Jan. 10, 2008 - Hythiam, Inc. (NASDAQ:HYTM) announced today that the United States Patent and Trademark Office has allowed Hythiam's U.S. Patent Application No. 10/621,229 which contains claims using a composition of matter for reducing a person's desire to drink alcohol. The patent will serve to enhance protection of the intellectual property underlying the company's PROMETA Treatment Program.
This patent, the second allowance in the U.S., represents the securing of the last of the initial patents in both Europe and the U.S. To date, Hythiam has been granted or allowed 56 patents throughout the world. The company believes that just as meaningful, however, are the continuation in part ("CIP") applications derived from this initial work that have been and will continue to be filed, as well as entirely distinct patent applications for treatment approaches for other CNS indications in which GABA receptor dysregulation may serve as the critical pathology.
No comments:
Post a Comment